Clinical Trial: Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy

Brief Summary: The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Detailed Summary: To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.
Sponsor: Johann Wolfgang Goethe University Hospital

Current Primary Outcome: BCVA in EDTRS values [ Time Frame: 24 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: OCT, leakage in FA, defects in satic perimetry [ Time Frame: 24 months ]

Original Secondary Outcome: Same as current

Information By: Johann Wolfgang Goethe University Hospital

Dates:
Date Received: December 4, 2008
Date Started: May 2007
Date Completion:
Last Updated: September 26, 2012
Last Verified: September 2012